{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=32", "query": { "intervention": "Monoclonal antibody - Dose Escalation", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 887, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:20:42.507Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00991562", "title": "IMGN901 in Combination With Lenalidomide and Dexamethasone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "IMGN901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-12", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-21", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 9, "location_summary": "Los Angeles, California • Palm Springs, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991562" }, { "nct_id": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT538", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Monoclonal antibody - Dose Escalation", "type": "COMBINATION_PRODUCT" }, { "name": "Monoclonal antibody - Dose Expansion", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-15", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05069935" }, { "nct_id": "NCT01828086", "title": "Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Plaque-type Psoriasis" ], "interventions": [ { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 95, "start_date": "2013-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 18, "location_summary": "Anniston, Alabama • Anaheim, California • Encino, California + 14 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01828086" }, { "nct_id": "NCT04419181", "title": "Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2025-08-11", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419181" }, { "nct_id": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2019-11-11", "completion_date": "2025-12-05", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143711" }, { "nct_id": "NCT05275998", "title": "TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "TMB-365/TMB-380", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TaiMed Biologics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 51, "start_date": "2022-07-05", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 6, "location_summary": "San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05275998" }, { "nct_id": "NCT00993044", "title": "A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Solid Tumors in Children" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "20 Years", "sex": "ALL", "summary": "12 Months to 20 Years" }, "enrollment_count": 13, "start_date": "2009-09", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00993044" }, { "nct_id": "NCT04634552", "title": "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2021-02-01", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634552" }, { "nct_id": "NCT04752826", "title": "BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Ovarian Cancer", "T-cell Lymphoma", "Melanoma" ], "interventions": [ { "name": "BI-1808", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection", "type": "DRUG" }, { "name": "Paclitaxel 80 mg/m2 weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioInvent International AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2021-01-25", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752826" }, { "nct_id": "NCT03190278", "title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "UCART123v1.2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cellectis S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 29, "start_date": "2017-06-19", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-17T09:20:42.507Z", "location_count": 8, "location_summary": "San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190278" } ] }